THE THYROID HORMONES thyroxine (T 4 ) and 3,3Ј,5-triiodo-L-thyronine (T 3 ) are major regulators of development, differentiation, and metabolism and are essential for the proper function of nearly all tissues. In the adult, the main function of thyroid hormones is the regulation of the basal metabolic rate, i.e., the rate of energy metabolism required to maintain cellular function at rest (31, 45) . Thyroid hormones exert their multiple effects via genomic and nongenomic modes of action (4) . They primarily regulate transcription of a broad range of target genes by binding to thyroid hormone receptors (TRs), which are members of the nuclear receptor superfamily.
The influence of thyroid hormones on gene expression has been studied extensively in a variety of skeletal muscles and species (2, 5, 7, 19, 39, 40, 46) . T 3 has been shown to exert significant effects on the metabolic and contractile properties of adult skeletal muscles (3, 30) . Decreased T 3 levels in humans and in experimental animals cause muscle weakness, sluggish movements, and pain. In contrast, hyperthyroid conditions in experimental animals cause an increase in mitochondria and mitochondrial enzymes and an increased percentage of fast-twitch fibers in skeletal muscles and induce slow-to-fast myosin heavy chain (MyHC) conversions (15) . Despite tissuespecific variations in the response of some genes, particularly those encoding the various MyHC isoforms (19) , the changes observed after administration of thyroid hormones are of the same tenor in all muscles investigated so far: 1) increased protein synthesis and degradation resulting in a net loss of protein and 2) increased energy consumption, mainly due to thermogenesis and stimulation of mitochondrial oxidative phosphorylation (1, 29) . A comprehensive expression study analyzing the transcriptional profile of hyperthyroid skeletal muscles indicated the upregulation of several other pathways, including signal transduction cascades and intracellular transport (7) .
Some muscle groups with extraordinary functional specialization show patterns of gene expression that are distinct from those seen in the prototypical limb skeletal muscles; such highly specialized muscle variants have been termed "muscle allotypes" (17) . The extraocular muscles (EOMs) are among these "allotypes": they are highly adapted to the control of eye movement, and their unique composition enables the visual system to rapidly search for, spot, and track objects with extreme precision. The functional requirements for EOMs cover a wide range of different movements, including vestibuloocular and optokinetic eye reflexes, as well as the rapid saccadic motions required for acquisition of a new target. In addition, EOMs rest only rarely, requiring considerable fatigue resistance (11, 33) . EOMs also differ in many other functionally significant ways from skeletal muscles, including differences in innervation, development, structural proteins, and susceptibility to disease (reviewed in Refs. 32, 33) .
Little is known about the effects of thyroid hormones on the properties of EOM fibers, even though EOMs are often prominently involved in thyroid eye diseases and uncontrolled overor underactivity of the thyroid is associated with severe ophthalmopathy. Such effects have been particularly neglected in diseases in which levels of T 3 are altered but that have other causes, such as the autoimmune mechanism that associates Graves' hyperthyroidism and Graves' ophthalmopathy. Experimental hypothyroidism in rats has been shown to result in a switch from fast-twitch to slow-twitch fibers in EOMs, and in hypothyroid humans the velocity of saccadic eye movements may be decreased (41) . The profound effects of thyroid hormone imbalances on the function of skeletal muscle fibers suggest that altered T 3 levels could have important influences on the performance of EOM fibers. However, their unique developmental origin, structural and functional properties, and singular reactions to diseases suggest that EOMs may also demonstrate unique responses to thyroid dysfunction. We have tested this hypothesis by conducting a comparison of gene expression in EOMs of euthyroid and T 3 -treated rats.
MATERIALS AND METHODS
Animals. Adult Sprague-Dawley rats (initial body wt 200 Ϯ 40 g) were fed ad libitum with standard laboratory diet and tap water. Eight rats were randomly divided into a T 3-treated and a control group, three males and one female each.
To simulate a chronically hyperthyroid state, 25 g of T 3 (SigmaAldrich, St. Louis, MO) per 100 g of body weight were administered by intraperitoneal injections every second day over a period of 6 wk. A second set of seven rats was grouped and treated analogously for independent verification of the microarray data by quantitative realtime PCR (qRT-PCR). Three animals of this second set received T 3 treatment, and four served as control group.
Twenty-four hours after the last injection, the animals were killed by CO 2 asphyxiation. Blood was taken from the body cavity. For RNA isolation, soleus muscle, tibialis anterior muscle (TA), and the EOMs were removed, flash-frozen in liquid nitrogen, and stored at Ϫ80°C until further use.
All procedures involving rats were reviewed and approved by the University of Pennsylvania's Institutional Animal Care and Use Committee.
Radioimmunoassays. Levels of free T 3 in serum of experimental animals were determined with the MP Biomedicals Free T3 125 I RIA kit (MP Biomedicals, Solon, OH), according to the manufacturer's recommendations. In brief, serum samples were added to anti-T 3 antibody-coated tubes and incubated with a solution containing radioactively marked T 3 for 2.5 h at 37°C. Subsequently, the tubes were rinsed with water, and levels of radioactivity were measured with a gamma counter. Levels of free T 3 were then calculated based on a standard curve.
Serum levels of thyroid-stimulating hormone (TSH) were determined with the MP Biomedicals TSH 125 I immunoradiometric assay (IRMA) kit, according to the manufacturer's recommendations. Briefly, serum samples were added to tubes coated with anti-TSH antibodies and incubated with radioactively marked anti-TSH antibodies with a different epitope specificity for 3 h at 37°C. After rinsing with water, radioactivity levels were measured with a gamma counter. Levels of TSH were then calculated based on a standard curve.
RNA isolation and quality controls. RNA was isolated with TRIzol Reagent (Invitrogen Life Technologies, Carlsbad, CA) and purified with an RNeasy Mini or Micro Kit (Qiagen, Valencia, CA), as recommended by the manufacturers. To prevent RNA degradation, SUPERase-In RNase Inhibitor (Ambion, Austin, TX) was added to the samples to a final concentration of 1 U/l. Purified RNA was stored at Ϫ80°C until further use. Microarray-grade purity and integrity of the isolated RNA were verified by spectrometry (absorbance A 260-to-A280 ratio between 1.8 and 2.2) and capillary electrophoresis with an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Microarrays. RNA isolated from EOMs and TA was processed for hybridization to Affymetrix GeneChip Rat Genome 230 2.0 Array chips (Affymetrix, Santa Clara, CA) with the One-Cycle Target Labeling and Control Reagents package (Affymetrix), as recommended by the manufacturer. Each chip was treated with individual RNA samples from separate animals. In brief, 1 g of total RNA was reverse-transcribed to single-stranded cDNA, using T7-oligo(dT) Promoter Primer and Superscript II reverse transcriptase. Subsequently, the second strand was confected by DNA polymerase I. The doublestranded cDNA was converted to biotinylated cRNA by in vitro transcription with T7 RNA polymerase. Finally, cRNA was purified and broken down into fragments of 35-to 200-bp length. Fifteen micrograms of cRNA from each sample were hybridized to the Rat Genome 230 2.0 Array chips for 16 h. Posthybridization washes and staining were performed with standard procedures on an Affymetrix GeneChip Fluidics Station 450; fluorescence was measured with a GCS3000 7G laser scanner (Affymetrix). Data were analyzed with GeneChip Operating Software (GCOS) 1.4 (Affymetrix) and GeneSpring 7.2 (Silicon Genetics, Redwood City, CA) (13) . Average signal intensities of the arrays were scaled to a default target signal value of 150. No normalization procedure was applied. The average 3Ј-to-5Ј ratio of GAPDH gene detection was 1.86 Ϯ 0.24 (SE) and of ␤-actin was 2.98 Ϯ 0.38 (SE). All primary data have been deposited at the Gene Expression Omnibus database (www.ncbi.nlm.nih.gov/ geo; accession no. GSE13436).
Genes with statistically significant changes in gene expression were identified with Significance Analysis of Microarrays (SAM) 2.23b (available for free download at www-stat.stanford.edu/ϳtibs/SAM) (38) . The false discovery rate (FDR) was adjusted to 7.1% for EOMs and to 7.8% or 15.1% for TA.
The resulting sets of differentially expressed genes were analyzed with Database for Annotation, Visualization, and Integrated Discovery (DAVID) 2.1 (8) and Ingenuity Pathways Analysis (IPA) 4.0 (Ingenuity Systems, www.ingenuity.com). Information about individual genes was ascertained from Information Hyperlinked over Proteins (iHOP; www.ihop-net.org) (16), NetAffx Analysis Center (Affymetrix, www.affymetrix.com/analysis/ index.affx) (23) , and the National Center for Biotechnology Information (NCBI, www.ncbi.nlm.nih.gov).
Quantitative RT-PCR. Five hundred nanograms of RNA isolated from EOMs and TA of the second, independent group of T3-treated and control animals were reverse-transcribed to cDNA by use of the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen Life Technologies) according to the manufacturer's protocol. Oligo(dT)12-18 primers were used for the reaction, thus selecting for mRNA to be reversetranscribed. cDNA was stored at Ϫ20°C until needed.
qRT-PCR was performed in a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) with Power SYBR Green PCR Mastermix (Applied Biosystems), 5 ng of cDNA, and each primer at 0.5 M. The following 10 genes were selected arbitrarily from the SAM list of genes with significantly altered gene expression: C1qbp (primer pair: 5Ј-AACGGCACGGAG-
, and Ywhae (5Ј-TGGCGAGTCCAAGGTTTCCT-3Ј/5Ј-TGTTCTCTGCTGCCTCCTTCC-3Ј).
␤-Actin (5Ј-TCTGTGTGGATTGGTGGCTCT-3Ј/5Ј-GACTCAT-CGTACTCCTGCTTGCT-3Ј) served as internal control (25) . Specificity of all primers was confirmed by Nucleotide-Nucleotide Blasts. For Gdf8, qRT-PCR was additionally performed with a highly specific TaqMan MGB probe (Applied Biosystems), with the corresponding primers designed and optimized by Applied Biosystems (Assays Rn00569683_m1 [myostatin] and Rn00667869_m1 [beta actin]).
Data were analyzed with the comparative ⌬⌬Ct relative quantitation method, where Ct is threshold cycle (24) .
qRT-PCR was performed accordingly with RNA from soleus muscle of T 3-treated and control animals to relatively quantify expression of Myh1 (5Ј-GAAGGCCAAGAAAGCCATC-3Ј/5Ј-GGT-CACTTTCCTGCTTTGGA-3Ј) (44) . Again, mRNA levels of ␤-actin were used as an internal control.
Fiber size measurements. Tissue covered in Tissue Freezing Medium (Triangle Biomedical Sciences, Durham, NC) on dissection was cut in transverse sections of 12-m thickness with a Zeiss Microm HM 500 cryostat (Carl Zeiss, Oberkochen, Germany) and attached to positively charged Fisherbrand Colorfrost/Plus microscope slides (Fisher Scientific, Pittsburgh, PA). Sections were stored at Ϫ80°C until use.
To measure average fiber areas, sections were fixed in cold 100% methanol and subsequently stained with goat anti-laminin antibody (Sigma-Aldrich) and Hoechst 44442 nuclear stain (Sigma-Aldrich). Pictures of the stained sections were taken with an Olympus BX51 microscope (Olympus America, Melville, NY) and analyzed with Scion Image (Scion, Frederick, MD). Individual fibers were outlined manually with Scion Image, which subsequently calculated the area. For each section, Ͼ200 individual fibers from representative areas of the muscle were measured. The statistical significance of differences between the fiber areas of hyperthyroid and control tissue of EOMs or TA was determined with the Mann-Whitney test.
RESULTS
Confirmation of hyperthyroid conditions. Determination of free T 3 and TSH levels in serum showed higher levels of T 3 and lower levels of TSH in the blood of T 3 -treated animals, consistent with T 3 injections and the negative feedback loop connecting thyroid hormones and TSH release. Thus these results confirmed that 6 wk of T 3 injections had indeed left the treated rats in a state effectively simulating hyperthyroidism (Fig. 1, A and B) . Correspondingly, the T 3 -treated rats experienced weight loss relative to the control group (data not shown). Several reports have demonstrated the induction of specific MyHC isoforms under chronically hyperthyroid conditions (42, 47) . Thus, to provide further evidence for the efficacy of T 3 injections, the relative gene expression of myosin heavy chain 1 (Myh1) in the soleus muscle was compared between T 3 -treated and control animals by qRT-PCR. As expected, a significant increase was detected in the T 3 -treated group (Fig. 1C) .
Extraocular muscles are highly responsive to thyroid hormones. SAM with a FDR of 7.1% yielded a list of 468 genes with significantly altered gene expression in EOMs (hereafter referred to as the EOM list; see Supplemental Table S1 ).
1 Fold changes ranged from Ϫ3.8 to 1.6, but only two genes showed increased expression in the T 3 -treated group; 466 transcripts were downregulated. With DAVID, 102 (22%) of the genes could be grouped by the biological processes in which they participate ( Fig. 2 and Supplemental Table S2 ). Several genes were part of more than one class of process. By far the largest group of affected transcripts was involved in cellular metabolism (74 genes); other prominent groups included transport (36 genes), biosynthesis (25 genes), protein localization (11 genes), and cell homeostasis (5 genes).
IPA detected 12 major networks of genes directly or indirectly regulating each other, representing a wide range of main functions ( Fig. 3 and Supplemental Table S3 ). IPA also recognized 15 canonical pathways that were significantly altered ( Fig. 4 and Supplemental Table S4 ), 6 of which involved metabolism of amino acids. Oxidative phosphorylation included 17, the highest number of altered genes.
Tibialis anterior shows moderate changes in gene expression. SAM of the TA data set with an FDR of 7.8% discovered only 20 significantly changed genes. Since DAVID analysis of these genes gave no conclusive results, SAM was repeated with a 15.1% FDR, yielding a list of 134 genes (hereafter referred to as the TA list; see Supplemental Table S5 ). Fold changes ranged from Ϫ1.7 to 3.6; 39 transcripts were downregulated and 95 showed increased expression in TA from T 3 -treated animals. DAVID analysis could classify 15 of these genes ( Fig. 5 and Supplemental Table S6) .
Surprisingly, only six genes displayed changes in their mRNA level in both EOMs and TA. Of these six, only the 1 The online version of this article contains supplemental material. 
Validation of microarray results by qRT-PCR.
To further assess the validity of the microarray results, 10 genes were selected arbitrarily from the EOM list and their relative expressions were analyzed by qRT-PCR (see Table 1 ). The genes for complement component 1, q subcomponent binding protein (C1qbp), myostatin (Gdf8), heat shock 90-kDa protein 1, ␤ (Hsp90ab1), heme oxygenase 2 (Hmox2), insulin-like growth factor-binding protein 5 (Igfbp5), sarcoglycan ⑀ (Sgce), thyroid hormone receptor ␣ (Thra), and tyrosine 3-monooxygenase (Ywhae) all showed a relative decrease in expression in EOMs of T 3 -treated rats consistent with the EOM list. Myotrophin (Mtpn) and tropomodulin 1 (Tmod1), however, did not display any significant changes in their relative gene expression. Additionally, expression of these 10 genes was analyzed with TA-derived RNA, even though only C1qbp had been detected by microarray analysis to have altered gene expression in TA. Some genes showed changes in the same direction as in EOMs (C1qbp, Hsp90ab1, Ywhae), one in the opposite direction (Igfbp5), and some did not show significant changes at all (Gdf8, Hmox2, Mtpn, Sgce, Thra, Tmod1) (see Table 1 ). Fig. 2 . Biological processes in which genes with significantly altered gene expression in extraocular muscles (EOMs) after T3 treatment are involved, according to DAVID 2.1. Note that several genes were grouped to Ͼ1 biological process. Because of its pivotal role in muscle regeneration and growth (6, 26, 27, 48) , special interest was taken in the changes in gene expression of myostatin. To further confirm its negative regulation by T 3 in EOMs, a highly specific TaqMan MGB probe was used for qRT-PCR with every available cDNA sample. All results indicated a downregulation of myostatin in EOMs of T 3 -treated animals. In TA-derived RNA, no significant change in myostatin transcripts was observed after T 3 treatment.
Myostatin has been reported to be a negative regulator of muscle growth (26, 27) . Moreover, Zhu et al. (48) induced hypertrophy without hyperplasia in transgenic mice with a dominant-negative mutation of myostatin. Because myostatin expression was decreased in T 3 -treated EOMs, an increase in extraocular fiber size was expected. With a laminin antibody, the basement membrane surrounding myotubes was stained and thus the outline of myofibers marked. Hence, individual fibers could easily be identified and the average fiber areas could be measured. Despite a considerable standard deviation due to the basic differences in fiber size between the orbital and global layers, fiber area in EOMs of T 3 -treated animals was significantly increased by 15.6% (Ϯ3.6% SE) relative to EOMs from control animals (data not shown). Analogous measurements indicated a decrease of fiber area in TA of T 3 -treated animals (data not shown).
DISCUSSION

Extraocular muscles respond to thyroid hormone in a unique
fashion. The present study provides the first comprehensive profile of thyroid hormone-induced changes in gene expression of EOMs, using rats as an experimental animal model. TA was used as a fast-twitch reference muscle. In EOMs, significant alterations were detected in 468 of the Ͼ30,000 transcripts covered by the microarray, whereas changes in TA were limited to 134 transcripts. qRT-PCR with arbitrarily selected genes confirmed the microarray results in an independent group of animals.
On the basis of our findings, we propose that EOMs respond to hyperthyroid conditions in a unique fashion that, in several aspects, is antithetical to the response patterns observed in other skeletal muscles.
Energy metabolism. Under aerobic conditions, mammalian skeletal muscles satisfy their energy demands mainly by oxidative phosphorylation in mitochondria. Hyperthyroid hindlimb skeletal muscles have been shown to exhibit increased levels of several components of the respiratory chain (2, 43) . A comprehensive microarray study with human skeletal muscle reported upregulation of 13 genes involved in oxidative phosphorylation (7) .
By contrast, the present study strongly suggests downregulation of oxidative phosphorylation in hyperthyroid EOMs. Seventeen transcripts associated with this pathway had significantly decreased levels of expression (Fig. 4 and Supplemental Table S4 ). Interestingly, none of the specific subunits downregulated in EOMs from T 3 -treated animals was upregulated in the human skeletal muscle study.
Similarly, the citric acid cycle, main source of the reducing agents NADH/H ϩ and FADH 2 for oxidative phosphorylation and central joint of carbohydrate, fatty acid, and amino acid metabolism, shows increased activity in limb muscles after treatment with thyroid hormone in both rats (9) and humans (7) . The citric acid cycle oxidizes acetyl-CoA to CO 2 and CoA, while storing the released energy mainly as reducing agents. dos Santos et al. (9) showed increases in citrate synthase and succinate dehydrogenase, the former being a key regulator of the citric acid cycle. For humans, the microarray study of Clement et al. (7) demonstrated upregulation of two components of the pyruvate dehydrogenase multienzyme complex, which catalyzes decarboxylation of pyruvate to acetyl-CoA and is another key regulator of the citric acid cycle, and of one subunit of succinyl-CoA synthetase. Moreover, the study indicated upregulation of glutamate dehydrogenase 1 and 3-oxoacid CoA transferase; both enzymes play a role in supplying intermediates of the cycle from sources other than acetyl-CoA.
Again, EOMs seem to respond conversely: two subunits of the succinate dehydrogenase complex, one subunit of isocitrate dehydrogenase, and mitochondrial malate dehydrogenase were all downregulated. Additionally, an isoform of pyruvate dehydrogenase, as well as glutamate dehydrogenase 1, were downregulated (see Table 2 ).
Up to 70% of the energy required in resting skeletal muscle is provided by lipid catabolism (36) . Although relatively little is known about the exact changes in this pathway under hyperthyroid conditions, an increase in fatty acid utilization by both triacylglycerol synthesis and ␤-oxidation has been re- Fold changes (ϮSE) in mRNA expression levels relative to respective controls as determined by quantitative real-time PCR (qRT-PCR) and Significance Analysis of Microarrays (SAM) are shown. EOM, extraocular muscle; TA tibialis anterior muscle; C1qbp, complement component 1 q subcomponent binding protein; Gdf8, myostatin; Hmox2, heme oxygenase 2; Hsp90ab1, heat shock 90-kDa protein 1␤; Igfbp5, insulin-like growth factor-binding protein 5; Mtpn, myotrophin; Sgce, sarcoglycan ε; Thra, thyroid hormone receptor ␣; Tmod1, tropomodulin 1; Ywhae, tyrosine 3-monooxygenase. Statistical significance was evaluated by Student's t-test. *P Ͻ 0.05, †P Ͻ 0.01, ‡P Ͻ 0.001; n.s., not significant; N/A, not applicable, because not represented on the TA list. ported in isolated, hyperthyroid rat soleus muscle (12) . During ␤-oxidation, fatty acids are broken down into several molecules of acetyl bound to CoA, stepwise in several cycles of the same reaction, under reduction of NAD ϩ and FAD. In EOMs of T 3 -treated animals two of the four enzymes mainly responsible for this process were downregulated, with two isoforms affected each (acetyl-coenzyme A acetyltransferase 1 and acetyl-coenzyme A acyltransferase 2; hydroxyacyl-coenzyme A dehydrogenase and hydroxyacyl-coenzyme A dehydrogenase, type II). Moreover, the rate-limiting import of fatty acids into the mitochondrial matrix was downregulated at all three steps: carnitine O-octanoyltransferase (an isoform of carnitine acyltransferase I), solute carrier family 25 member 20 (an isoform of carnitine/acylcarnitine translocase), and carnitine palmitoyltransferase 2 (an isoform of carnitine acyltransferase II) all showed decreased gene expression in EOMs of T 3 -treated animals. 2,4-Dienoyl CoA reductase 1, an enzyme involved in the mitochondrial elongation of very long fatty acids (i.e., longer than palmitate), was also found to be downregulated (see Table 2 ).
Degradation of amino acids usually provides for only 10 -15% of the energy needs of the human body (22) . The main organ for amino acid degradation is the liver, with the exception of valine, leucine, and isoleucine, which are primarily utilized by muscles, adipose tissue, the kidneys, and the brain. Oxidation of these branched amino acids requires the enzyme branched-chain aminotransferase, which also was downregulated in hyperthyroid-like EOMs. Likewise, isoforms of the enzymes glutamate dehydrogenase, glutaminase, and aspartate aminotransferase (glutamate oxaloacetate transaminase 1), all of which are central to amino acid catabolism, showed decreased expression (see Table 2 ).
Taken together, EOMs of T 3 -treated rats displayed decreased expression of enzymes representing all pathways pertaining to so-called "energy production," both aerobic and anaerobic. The most likely result of this observation is a marked decrease in energy provided in EOMs, implying either shortage of energy in or decreased energy demands by myotubes under T 3 treatment. In stark contrast, all reports about other skeletal muscles to date have consistently reported significant increases in lipid and carbohydrate metabolism under hyperthyroid conditions.
Possible mechanisms of T 3 action in extraocular muscles. The results of this study clearly document a unique response of EOMs to hyperthyroid conditions. Whereas previous studies on various hyperthyroid non-EOM skeletal muscles consis- Fold change of mRNA levels relative to untreated controls, as determined by microarray analysis, is shown. T3, 3,3Ј,5-triiodo-L-thyronine.
tently reported an increase in enzymes of the citric acid cycle, oxidative phosphorylation, protein biosynthesis, and protein degradation, EOMs of T 3 -treated rats showed downregulation of the expression of enzymes from all these pathways. Moreover, the only other comprehensive gene expression study on hyperthyroid skeletal muscle published to date (7) reported significant changes in the expression of 383 genes, 381 of which were upregulated. Similarly, 71% of the genes on the TA list were upregulated. By contrast, 466 of the 468 transcripts on the EOM list were downregulated. There are three different models that might explain the molecular mechanism of this paradoxical response by EOMs to elevated T 3 levels. First, the most straightforward explanation is an EOM-specific regulatory activity of thyroid hormones. This could be mediated, for instance, by specific constellations of TR, retinoid X receptor (RXR), which can form heterodimers with TR and modulate its effects on transcription (21) , and other cofactors of transcriptional regulation. While TR expression levels are thought not to differ significantly between EOMs and other skeletal muscles, RXR-␣ and -␥ have been shown to be expressed at much lower levels in EOMs (10, 11) . This differential expression pattern might contribute to or even cause the phenotype reported here. Also, hitherto unknown EOM-specific isoforms of TR or RXR are conceivable. This model is supported by reports of tissue-specific, opposite regulation of single genes by thyroid hormone. For instance, enolase has been shown to be differentially regulated in rat skeletal and cardiac muscle development (28) . Interestingly, thyroid hormone receptor ␣ (Thra) was downregulated in EOMs from T 3 -treated animals, but not in TA (Tables 1 and 2) . Second, T 3 may initially exert the same effects on EOMs as on every other skeletal muscle, which would include significant upregulation of oxidative activity. Because EOMs already feature a very high oxidative metabolism in the euthyroid state, any further increase could override the antioxidant defenses of EOM fibers and lead to severe cytotoxic effects through excessive oxidative stress. Subsequent to this damage, myofibers might fall into oxidative crisis, leading to downregulation of all major pathways, potentially even necrosis. The fact that almost all genes that are significantly altered in EOMs of T 3 -treated animals are downregulated supports this interpretation, as does the overall consistency of responses to hyperthyroidism in other skeletal muscles. The increase in myofiber size reported here might then be due to cellular swelling as an early stage of necrosis. Also, necrosis could explain at least part of the lymphocyte infiltration seen in Graves' ophthalmopathy.
Third, at least part of the changes in gene expression of EOMs from T 3 -treated rats observed in this study may be not a primary effect of increased T 3 levels but rather a secondary effect produced by downregulation of myostatin (also known as growth and differentiation factor 8, Gdf8). Myostatin, a member of the transforming growth factor-␤ (TGF-␤) superfamily, is a negative regulator of muscle growth. Loss-offunction mutations in the myostatin gene lead to increased skeletal muscle size in vivo. This is exemplified by the naturally occurring "double-muscled" cattle, which were first noted more than 200 years ago and more recently have been shown to carry myostatin mutations (14, 20, 27) . Importantly, "double-muscled" cattle have been reported to display reduced aerobic metabolic activity (18) , consistent with the decrease in the expression of enzymes involved in lipid catabolism shown here. Moreover, a recently published microarray study profiling skeletal muscle gene expression in myostatin-knockout mice found multiple genes downregulated that also showed decreased expression in EOMs of T 3 -treated rats, notably components of oxidative phosphorylation and antioxidant enzymes (37) . Significantly, we have also shown that EOMs of hyperthyroid mice show the same decrease in myostatin (N. A. Rubinstein, T. S. Khurana, and S. Bose, unpublished observations).
The finding of decreased myostatin in EOMs of T 3 -treated animals may also bear clinical relevance. Graves' ophthalmopathy frequently occurs as a complication of Graves' disease and is consequently associated with hyperthyroidism. It is an autoimmune disease that is commonly attributed to antibodies directed against the TSH receptor, which is expressed in both thyroid and orbital tissue, resulting in marked EOM dysfunction. The autoimmune response causes edema in EOMs, production of glycosaminoglycans by orbital fibroblasts, and hyperplasia of adipose tissue. These, in turn, lead to proptosis and compression of the optic nerve, and eventually can cause diplopia and loss of vision (34, 35) . It is possible, however, that decreased myostatin in such patients may also contribute to swelling of the orbital contents, in this case by causing EOM fiber hypertrophy. Should further work corroborate this hypothesis, topical low-dose application of myostatin may provide a minimally invasive way to symptomatic relief for patients suffering from Graves' ophthalmopathy.
